Does crossover treatment of control subjects invalidate results of randomized trials of patent ductus arteriosus treatment?
Optimal management of patent ductus arteriosus (PDA) in extremely preterm infants remains controversial. There is paucity of evidence on the benefits of PDA treatment in reducing mortality and morbidities in extremely preterm infants. Failure of randomized clinical trials to demonstrate beneficial e...
| Publicado en: | Journal of Perinatology Vol. 40; no. 12; pp. 1863 - 1871 |
|---|---|
| Autores principales: | , |
| Formato: | tables/charts Journal Article |
| Publicado: |
Springer Nature
Dec2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |